Perinatal Illicit Drug and Marijuana Use
- PMID: 26559718
- PMCID: PMC4864182
- DOI: 10.4278/ajhp.141215-QUAL-625
Perinatal Illicit Drug and Marijuana Use
Abstract
Purpose: To assess use, screening, and disclosure of perinatal marijuana and other illicit drugs during first obstetric visits.
Design: Observational study that qualitatively assesses provider screening and patient disclosure of substance use.
Setting: Study sites were five urban outpatient prenatal clinics and practices located in Pittsburgh, Pennsylvania.
Participants: Pregnant patients and obstetric providers were recruited as participants.
Methods: We audio recorded patient-provider conversations during first obstetric visits and obtained patient urine samples for drug analyses. Audio recordings were reviewed for provider screening and patient disclosure of illicit drug use. Urine analyses were compared with audio recordings to determine disclosure.
Results: Four hundred and twenty-two pregnant patients provided complete audio recordings and urine samples for analyses. Providers asked about illicit drug use in 81% of the visits. One hundred twenty-three patients (29%) disclosed any current or past illicit drug use; 48 patients (11%) disclosed current use of marijuana while pregnant. One hundred and forty-five samples (34%) tested positive for one or more substances; marijuana was most commonly detected (N = 114, 27%). Of patients who tested positive for any substance, 66 (46%) did not disclose any use; only 36% of patients who tested positive for marijuana disclosed current use.
Conclusion: Although marijuana is illegal in Pennsylvania, a high proportion of pregnant patients used marijuana, with many not disclosing use to their obstetric care providers.
Keywords: Communication; Health focus: illicit drug use; Marijuana; Outcome measure: behavioral; Physician Counseling; Pregnant Women; Prenatal Care; Prevention Research. Manuscript format: research; Research purpose: descriptive; Setting: outpatient obstetrics clinics and offices; Strategy: patient-provider screening communication; Study design: qualitative; Target population age: adult reproductive-age women (18 to 44 years); Target population circumstances: pregnant women and obstetric care providers.
Figures
Similar articles
-
Obstetric Health Care Providers' Counseling Responses to Pregnant Patient Disclosures of Marijuana Use.Obstet Gynecol. 2016 Apr;127(4):681-687. doi: 10.1097/AOG.0000000000001343. Obstet Gynecol. 2016. PMID: 26959210 Free PMC article.
-
A comparison of common practices for identifying substance use during pregnancy in obstetric clinics.Birth. 2019 Dec;46(4):663-669. doi: 10.1111/birt.12426. Epub 2019 Mar 27. Birth. 2019. PMID: 30916432
-
The Association Between Antenatal Maternal Self-reported Substance Use, Maternal Characteristics, and Obstetrical Variables.J Addict Med. 2019 Nov/Dec;13(6):464-469. doi: 10.1097/ADM.0000000000000521. J Addict Med. 2019. PMID: 31033670
-
Demographic and psychosocial characteristics of substance-abusing pregnant women.Clin Perinatol. 1999 Mar;26(1):55-74. Clin Perinatol. 1999. PMID: 10214543 Review.
-
Prenatal marijuana use: epidemiology, methodologic issues, and infant outcome.Clin Perinatol. 1991 Mar;18(1):77-91. Clin Perinatol. 1991. PMID: 2040119 Review.
Cited by
-
Obstetrician-gynecologists' practices and attitudes on substance use screening during pregnancy.J Perinatol. 2020 Mar;40(3):422-432. doi: 10.1038/s41372-019-0542-3. Epub 2019 Oct 30. J Perinatol. 2020. PMID: 31666646 Free PMC article.
-
Patient-Health Care Provider Conversations About Prenatal Genetic Screening: Recommendation or Personal Choice.Obstet Gynecol. 2016 Jun;127(6):1145-1152. doi: 10.1097/AOG.0000000000001433. Obstet Gynecol. 2016. PMID: 27159763 Free PMC article.
-
Development and validation of the Cannabis Exposure in Pregnancy Tool (CEPT): a mixed methods study.BMC Pregnancy Childbirth. 2024 Apr 16;24(1):280. doi: 10.1186/s12884-024-06485-0. BMC Pregnancy Childbirth. 2024. PMID: 38627667 Free PMC article.
-
Pregnant Women's Access to Information About Perinatal Marijuana Use: A Qualitative Study.Womens Health Issues. 2016 Jul-Aug;26(4):452-9. doi: 10.1016/j.whi.2016.03.010. Epub 2016 May 4. Womens Health Issues. 2016. PMID: 27131908 Free PMC article.
-
Associations between Prenatal and Postnatal Exposure to Cannabis with Cognition and Behavior at Age 5 Years: The Healthy Start Study.Int J Environ Res Public Health. 2023 Mar 10;20(6):4880. doi: 10.3390/ijerph20064880. Int J Environ Res Public Health. 2023. PMID: 36981794 Free PMC article.
References
-
- Chasnoff I. Chemical dependency and pregnancy. Clin Perinatol. 1991;18:1–191. - PubMed
-
- Ebrahim S, Gfroerer J. Pregnancy-related substance use in the United States during 1996–1998. Obstet Gynecol. 2003;101:374–379. - PubMed
-
- Sherwood R, Keating J, Kavvadia V, et al. Substance misuse in early pregnancy and relationship to fetal outcomes. Neonatology. 1999;158:488–492. - PubMed
-
- Oyelese Y, Ananth C. Placental abruption. Obstet Gynecol. 2006;108:1005–1016. - PubMed
-
- Bada H, Das A, Bauer C, et al. Low birth weight and preterm births: etologic fraction attributable to prenatal drug exposure. J Perinatol. 2005;25:631–637. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous